Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00704691 · ClinicalTrials.gov registry record · Early Phase 1

Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas

A Early Phase 1 study, sponsored by University of Alabama at Birmingham.

Terminated
Registry status
Early Phase 1
Development phase
1
Enrollment target

NCT00704691: Clinical Trial Early Phase 1 study, sponsored by University of Alabama at Birmingham.

NCT00704691 is a Early Phase 1 study that was terminated before completion, run by University of Alabama at Birmingham. The registered enrollment target is 1 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00704691, a Early Phase 1 study, was terminated before completion, sponsored by University of Alabama at Birmingham.

TERMINATED
Registry status
Early Phase 1
Development phase
1 participants
Enrollment target

Study Summary

The purpose of this study is to: * assess the effectiveness of lenalidomide for the treatment of patients with relapsed and or refractory peripheral T-cell lymphomas; and, * assess the safety of lenalidomide. There are reports suggesting a therapeutic benefit of thalidomide in patients with refractory and/or relapsed Non-Hodgkin's Lymphoma's (NHL) which have led to the formal investigation of lenalidomide in the treatment of relapsed NHL's.

Interventions

  • DRUG Lenalidomide

Trial Details

FieldValue
Enrollment Target 1 participants
Start Date 2008-06
Est. Completion 2009-12
Phase Early Phase 1
University of Alabama at Birmingham

1,160 total trials

Why NCT00704691 stopped before completion

NCT00704691 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (98% lower).

The record links to 0 conditions, and to 1 intervention - of which Lenalidomide is the first listed.

NCT00704691 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00704691 about?

NCT00704691 is a clinical study titled "Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas". The purpose of this study is to: * assess the effectiveness of lenalidomide for the treatment of patients with relapsed and or refractory peripheral T-cell lymphomas; and, * assess the safety of lenalidomide. There are reports suggesting a therapeutic benefit of thalidomide in patients with refrac...

What is the current status of trial NCT00704691?

This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 1 participants. The study started on 2008-06. Estimated completion is 2009-12.

What interventions are being tested in trial NCT00704691?

The interventions under investigation include: Lenalidomide (DRUG).

Who is sponsoring clinical trial NCT00704691?

This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00704691's enrollment target sits among peer trials

1 1985th of 2000 the lowest of 2,000 other Early Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00704691, the US trial registry maintained by the National Library of Medicine. NCT00704691 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.